Anticancer Effects Research Articles

In silico and in vitro inhibition abilities of novel benzene sulfonamides on carbonic anhydrase and choline esterases

Compounds that possess a benzene sulfonamide structure are utilized in a wide range of fields. It is reported in the literature that many compounds belonging to this class of compounds exhibit various pharmacological properties such as antibacterial, antifungal, antiviral, anticancer, inflammatory, antiglaucoma, and anticholinergic effects. Carbonic anhydrase (CA) enzymes play a critical role in pH regulation, long-term synaptic turnover and are therefore thought to be associated with such diseases as mental retardation, Alzheimer’s disease (AD) and Down syndrome. Studies have reported that there is an increase in the levels of hCA-I and hCA-II isoenzymes in AD. AD is a complex, multifactorial disorder, so therapy should probably address not only the cholinergic system but also additional systems. Based on these features, a series of novel substituted benzene sulfonamides were synthesized from 1,2,3-trimethoxy-5-methylbenzene. Sulfonyl chloride 9 was synthesized from the reaction of 1,2,3-trimethoxy-5-methylbenzene and excess chlorosulfonic acid. The reaction of the obtained sulfonyl chloride with NH3 and N-alkyl amines, aniline, and phenethylamine gave substituted benzene sulfonamide derivatives 10–16. The synthesized compounds were evaluated for their carbonic anhydrase (hCA I-II), acetyl cholinesterase (AChE) and butyryl cholinesterase (BChE) inhibitory properties. Some of the substituted benzene sulfonamide derivatives 10–16 showed inhibitory effect on hCA isoenzymes. The Ki values determined for the hCA I enzyme are in the range of 102.01–147.19 µM. Benzene sulfonamide derivatives 10–16 showed an inhibitory effect on AChE and BChE. The Ki values determined for AChE and BChE enzymes are in the range of 28.76–308.08 µM and 42.80–445.60 µM, respectively. It was determined that sulfonamides 15–16 were selective inhibitors for the hCA I and 10 showed 11-fold more selectivity on AChE than BChE. In addition, the in-silico SAR and ADME properties of the synthesized compounds were also investigated.

Abstract PR002: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer

Abstract Despite the tremendous success of PARP1 inhibitors (PARPi) for the treatment of BRCA mut tumors, intrinsic and acquired resistance to PARPi remains a critical challenge in the clinic. This is, at least in part, due to the incomplete understanding of the mechanism of action (MoA) of PARPi. Recent studies from both our lab and others have pointed to PARP1 trapping as a key determinant of the anticancer effects of PARP1 inhibitors (PARPi). However, the molecular underpinnings of PARP1 trapping are poorly understood. Here we performed a proteomics-based chromatin relocalization screen, and identified RNF114, as a PARylation-dependent, E3 ubiquitin ligase involved in DNA damage response. Upon sensing genotoxicity, RNF114 was recruited, in a PAR-dependent manner, to DNA lesions, where it targeted PARP1 for degradation. The blockade of this pathway interfered with the removal of PARP1 from DNA lesions, leading to profound PARP1 trapping. A unique feature of this pathway is its druggability. We showed that a natural product, nimbolide, inhibited the E3 ligase activity of RNF114 and thus caused PARP1 trapping. However, unlike conventional PARPi, nimbolide treatment induced the trapping of both PARP1 and PARylation-dependent DNA repair factors. The unique mechaism of action of nimbolide translated into its superior cytotoxicity against BRCA mut cancer cells, compared to regular PARPi. It is also able to potentially overcome intrinsic and acquired resistance to PARPi, both in vitro and in vivo. In collaboration with Dr. Tian Qin, we recently performed the first total synthesis of nimbolide via a pharmacophore-directed, late-stage coupling strategy. Using this method, we have obtained a large panel of novel nimbolide analogs with improved activity and drug-like properties. We have further garnered key SAR (structure-activity relationship) insights into nimbolide. These results point to the exciting possibility of translating nimbolide analogs into novel PARP1-targeting agents for the treatment of BRCA mut cancers. Citation Format: Peng Li, Yuanli Zhen, Chiho Kim, Zhengshuai Liu, Jianwei Hao, Heping Deng, Hejun Deng, Min Zhou, Xu-Dong Wang, Tian Qin, Yonghao Yu. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr PR002.

Pelargonidin inhibits cell growth and promotes oxidative stress‐mediated apoptosis in lung cancer A549 cells

AbstractLung cancer has the worst prognosis with an average 5‐year survival rate of only 10%–20%. Lung cancer has the highest prevalence rate and a second most common cause of cancer‐associated mortalities worldwide. The present study was planned to explore the anticancer effects of pelargonidin against the lung cancer A549 cells via analyzing oxidative stress‐mediated apoptosis. The viability of both control and pelargonidin‐treated A549 cells was analyzed using the MTT cytotoxicity assay at different time periods. The levels of endogenous ROS generation, mitochondrial membrane potential (Δψm), and apoptosis were assessed using corresponding fluorescent staining assays. The levels of oxidative stress biomarkers, including TBARS, SOD, CAT, and GSH, in the cell lysates of control and pelargonidin‐treated A549 cells were examined using the assay kits. The pelargonidin treatment substantially suppressed the A549 cell growth. Further, pelargonidin promoted the ROS production and depleted the Δψm levels in the A549 cells. The fluorescent staining assays witnessed the occurrence of increased apoptosis in the pelargonidin‐treated A549 cells. The pelargonidin also boosted the TBARS and reduced the antioxidant levels thereby promoted the oxidative stress‐regulated apoptosis in the A549 cells. In summary, the findings’ results of the current study demonstrated an anticancer activity of pelargonidin on A549 cells. The pelargonidin treatment substantially decreased the growth and encouraged the oxidative stress‐regulated apoptosis in A549 cells. Therefore, it was evident that the pelargonidin could be employed as an effective anticancer candidate to treat the lung cancer.

Cucurbitacin: Unveiling its Role as Phytomolecule in Health Benefits

Abstract: In recent scientific studies, a variety of phytochemicals, including carotenoids, polyphenols, isoprenoids, phytosterols, saponins, and dietetic fibers, besides polysaccharides, have been linked to beneficial health effects, which include reducing the risk of diabetes, obesity, and cancer, cardiovascular diseases, and other conditions. Squash, pumpkin, cucumber, and melons are just a few examples of the Cucurbitaceae family plants that contain cucurbitacins, highly oxygenated tetracyclic triterpenes. Since ancient times, various traditional remedies have been made from plants that contain cucurbitacins. Several cucurbitacins (A, B, C, D, E, F, G, I, J, K, L, O, P, Q, R, S) have an extensive assortment of bioactivities, including hepatoprotective activity, liver protection, anticancer, anti-inflammatory, antiviral, and anti-diabetic properties. Cucurbitacins, for instance, have a well-known anticancer effect. Specific reports suggest that cucurbitacins stimulate apoptosis via the JAK/STAT3 pathway. Through cyclin inhibition, cucurbitacins may inhibit the cell cycle. Besides, they expedite autophagy while preventing cancer cells from migrating and infecting other tissues. Cucurbitacins have been categorized as signal transducers and activators of transcription. It is soundly acknowledged that the plant-based compound cucurbitacin B (CuB) has insecticidal and repellent properties. CuB has been shown to have non-specific toxicity and limited bioavailability in studies evaluating its toxicity and pharmacokinetic characteristics. Hence, we aimed to concentrate on the numerous properties of cucurbitacins in this article, including their chemistry, an analysis of biosynthesis, several types of bioactivities, and studies on their toxicity.

Potential applications of antofine and its synthetic derivatives in cancer therapy: structural and molecular insights.

Cancer is a major global health challenge, being the second leading cause of morbidity and mortality after cardiovascular disease. The growing economic burden and profound psychosocial impact on patients and their families make it urgent to find innovative and effective anticancer solutions. For this reason, interest in using natural compounds to develop new cancer treatments has grown. In this respect, antofine, an alkaloid class found in Apocynaceae, Lauraceae, and Moraceae family plants, exhibits promising biological properties, including anti-inflammatory, anticancer, antiviral, and antifungal activities. Several molecular mechanisms have been identified underlying antofine anti-cancerous effects, including the inhibition of nuclear factor κB (NF-κB) and AKT/mTOR signaling pathways, epigenetic inhibition of protein synthesis, ribosomal targeting, induction of apoptosis, inhibition of DNA synthesis, and cell cycle arrest. This study discusses the molecular structure, sources, photochemistry, and anticancer properties of antofine in relation to its structure-activity relationship and molecular targets. Then, examine in vitro and in vivo studies and analyze the mechanisms of action underpinning antofine efficacy against cancer cells. This review also discusses multidrug resistance in human cancer and the potential of antofine in this context. Safety and toxicity concerns are also addressed as well as current challenges in antofine research, including the need for clinical trials and bioavailability optimization. This review aims to provide comprehensive information for more effective natural compound-based cancer treatments.

Pyrones isolated from Annona acutiflora exhibit promising cytotoxic effects on cancer cell lines.

This work discusses the ongoing challenge of cancer, focusing on therapy issues such as chemotherapy resistance and adverse drug effects. It emphasizes the need for new anticancer agents with improved efficacy and fewer side effects, exploring natural products from plant sources. The Annonaceae family, specifically the Annona genus, is highlighted for its medicinal properties, including anti-inflammatory and anticancer effects. The study focuses on the isolation and elucidation of the substances present in Annona acutiflora leaves. The methodology involves chromatographic and spectroscopy techniques. The isolated compounds, (6S)-5'-oxohepten-1'E,3'E-dienyl)-5,6-dihydro-2H-pyran-2-one (1), (6R)-5'-oxohepten-1'Z,3'E-dienyl)-5,6-dihydro-2H-pyran-2-one (2) and (6R)-5'-oxohepten-1'Z,3'E-dienyl)-5,6-dihydro-2H-pyran-2-one (3) were investigated for cytotoxicity assays on cancer cell lines and normal cells. Results show promising cytotoxic activity, particularly with compound 3, demonstrating potential activity against oral cancer (43.18µM), hepatocarcinoma (17.24µM), melanoma (5.39µM), and colon cancer (59.03µM). The compound outperforms carboplatin in selectivity against oral cancer (S.I. 2.15) and melanoma (S.I. 17.22). The study concludes by suggesting the potential of these α-pyrones as effective and less toxic alternatives for cancer therapy.

Assessment of the Anti-cancer Effects of Camel Milk Exosomes (CMEXOs) on Murine Colorectal Cancer Cell Line (CT-26)

Today, camel milk consumption in the Middle East is trendy because it is believed that it reduces the risk of cancer. Recently, studies have discovered that most of milk's beneficial effects are because of its nanoparticles, especially exosomes. The objective of the present research was to investigate the anti-cancer effects of camel milk exosomes (CMEXOs) in the murine colorectal cancer cell line (CT-26). Our findings verified the existence of exosomes measuring approximately 114.1±3.4 nm in diameter. Through MTT and migration assays, we established that CMEXOs exhibit dose-dependent anti-proliferative and anti-migration effects on the CT-26 cell line. Furthermore, our study showed that treatment with CMEXOs led to a reduction in TNF-α and IL-6 gene expression in CT-26 cells. While additional in vivo studies are required, our data demonstrate that CMEXOs have anti-proliferative and anti-migration effects on CT-26, possibly by influencing crucial genes within the inflammation pathway.

Andrographolide targets EGFR to impede epithelial–mesenchymal transition in human breast cancer cells

Despite the primary surgical treatment for breast cancer patients, malignant invasiveness and metastasis remain threatening factors for women with breast cancer. As chemotherapy yields unsatisfactory results, it prompted us to search for effective natural agents with few side-effects. Although andrographolide (ADGL), a natural diterpenoid lactone isolated from Andrographis paniculata, presents anticancer effects, the molecular mechanism remains unknown. Initially, on comparing the expression of proteins related to epithelial–mesenchymal transition (EMT) between nonmetastatic cancer MCF7 cells and highly metastatic cancer MDA-MB-231 cells, we found that MDA-MB-231 cells exhibit higher protein levels of N-cadherin and vimentin and lower protein levels of E-cadherin when compared to MCF7 cells. Moreover, MDA-MB-231 cells also exhibited higher EGFR expression and activity, higher STAT1 activity and abundant HDAC4 expression. To elucidate whether these proteins are closely associated with EMT, EGFR, STAT1 or HDAC4, the proteins were silenced in MDA-MB-231 breast cancer cells by their specific siRNAs. We found that silencing these proteins reduced EMT, indicating an important role of EGFR, STAT1 and HDAC4 in EMT progression. When we treated MDA-MB-231 cells with ADGL as a potential therapeutic drug, we found that ADGL treatment inhibited cell migration and invasion. Furthermore, it also recovered E-cadherin expression and decreased N-cadherin and vimentin protein levels. ADGL treatment reduced EGFR expression at a lower concentration (1 μg/mL); however, STAT1 activity and HDAC4 expression was reduced by a higher concentration (5 μg/mL) of ADGL. Moreover, we observed that the combined treatment with ADGL and siRNAs against these proteins highly sensitized the MDA-MB-231 cells to apoptosis compared to that with ADGL and control siRNA. Collectively, our results suggest that ADGL targets EGFR, thereby inhibiting EMT in human breast cancer cells.

Development of nanobigel system combining apoptosis-inducing daidzein and flaxseed oil for the synergistic treatment of skin cancer

Daidzein (DDZ), an isoflavone containing phytoestrogen, and flaxseed oil (FSO), an omega-3-polyunsaturated fatty acid rich dietary lipid, are known to exert anticancer effects via inducing apoptosis in cancer cells. However, oral administration of DDZ and FSO is associated with biopharmaceutical issues. This study aimed to develop a stable topical bigel (BG) system containing DDZ and FSO to exert synergistic effects in the treatment of skin cancer. High speed homogenization method was used for the preparation of DDZ-loaded bigel (DDZ@BG). In vitro investigations and morphological studies were performed to characterize the developed formulation. MTT cytotoxicity tests were conducted to evaluate the effect of the combination of DDZ and FSO on A431human skin cancer cell lines. To assess the toxicity, skin irritation studies using the Draize test was performed followed by histopathological analysis. The optimized DDZ@BG exhibited uniform texture, nanometric size and high drug content with sustained release profile and improved drug permeation. The MTT cytotoxicity studies revealed an IC50 value of 110.2 μg/mL for the optimized formulation. The developed nanobigel formulation exhibited high potential in the effective topical treatment of skin cancer with improved safety profile.

Pomegranate extract-loaded surfactant-free zein nanoparticles as a promising green approach for hepatic cancer: optimization and in vitro cytotoxicity

BackgroundHepatic cancer endures a major health scourge as the consequence of a high incidence of > 1 million cases by 2025. Plant-based products are typically effective in ameliorating health conditions. Pomegranate peel extract (PE) with its high polyphenolic content has anticancer effects against different types of cancer. Herein, we aimed to maximize the PE chemotherapeutic efficacy by loading it in a suitable delivery system to overcome the limitations of PE, to control its release and to achieve liver targeting.MethodA nanoprecipitation procedure was adopted to incorporate PE into biodegradable and biocompatible natural polymeric zein (ZN)-based nanoparticles (NPs) (PE-ZN NPs). A full factorial design (22 × 31) was developed to study the effects of the formulation variables, namely pH of dispersion, PE-to-ZN ratio and surfactant concentration.ResultsThe optimization revealed a surfactant-free stable PE-ZN NPs formula with a small particle size of 99.5 ± 6.43 nm, high PE encapsulation efficiency % of 99.31% ± 3.64 (w/w) and controlled release of PE over 24 h.ConclusionMoreover, the cytotoxicity of the optimum formula against hepatic cancer HepG2 cell lines was assessed and attained about a 2.5-fold reduction in the inhibitory concentration (IC50) values compared to the free PE affording a promising green platform to combat hepatic cancer.Graphical abstract

Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple‐negative breast cancer

AbstractTriple‐negative breast cancer (TNBC) is notoriously difficult to treat due to the lack of targetable receptors and sometimes poor response to chemotherapy. The transforming growth factor beta (TGFβ) family of proteins and their receptors (TGFRs) are highly expressed in TNBC and implicated in chemotherapy‐induced cancer stemness. Here, we evaluated combination treatments using experimental TGFR inhibitors (TGFβi), SB525334 (SB), and LY2109761 (LY) with paclitaxel (PTX) chemotherapy. These TGFβi target TGFR‐I (SB) or both TGFR‐I and TGFR‐II (LY). Due to the poor water solubility of these drugs, we incorporated each of them in poly(2‐oxazoline) (POx) high‐capacity polymeric micelles (SB‐POx and LY‐POx). We assessed their anticancer effect as single agents and in combination with micellar PTX (PTX‐POx) using multiple immunocompetent TNBC mouse models that mimic human subtypes (4T1, T11‐Apobec and T11‐UV). While either TGFβi or PTX showed a differential effect in each model as single agents, the combinations were consistently effective against all three models. Genetic profiling of the tumors revealed differences in the expression levels of genes associated with TGFβ, epithelial to mesenchymal transition (EMT), TLR‐4, and Bcl2 signaling, alluding to the susceptibility to specific gene signatures to the treatment. Taken together, our study suggests that TGFβi and PTX combination therapy using high‐capacity POx micelle delivery provides a robust antitumor response in multiple TNBC subtype mouse models.

Protective effects of silymarin in glioblastoma cancer cells through redox system regulation.

Glioblastoma multiforme, a deadly form of brain tumor, is characterized by aggressive growth and poor prognosis. Oxidative stress, a disruption in the balance between antioxidants and oxidants, is a crucial factor in its pathogenesis. Silymarin, a flavonoid extracted from milk thistle, has shown therapeutic potential in inhibiting cancer cell growth, promoting apoptosis, and reducing inflammation. It also regulates oxidative stress. This study aims to investigate the regulatory effects of silymarin on oxidative stress parameters, especially the transcription factor Nrf2 and its related enzymes in GBM cancer cells, to develop a new anti-cancer compound with low toxicity. First, the cytotoxicity of silymarin on U-87 MG cells was investigated by MTT and the results showed an IC50 of 264.6μM. Then, some parameters of the redox system were measured with commercial kits, and the obtained results showed that silymarin increased the activity of catalase and superoxide dismutase enzymes, as well as the total antioxidant capacity levels; while the malondialdehyde level that is an indicator of lipid peroxidation was decreased by this compound. The expression level of Nrf2 and HO-1 and glutaredoxin and thioredoxin enzymes were checked by real-time PCR method, and the expression level increased significantly after treatment. Our findings suggest that silymarin may exert its cytotoxic and anticancer effects by enhancing the Nrf2/HO-1 pathway through antioxidant mechanisms in U-87 MG cells.

Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1

BackgroundImmunotherapy for gastric cancer remains a challenge due to its limited efficacy. Metabolic reprogramming toward glycolysis has emerged as a promising avenue for enhancing the sensitivity of tumors to immunotherapy. Pyruvate dehydrogenase kinases (PDKs) play pivotal roles in regulating glycolysis. The importance of PDKs in the context of gastric cancer immunotherapy and their potential as therapeutic targets have not been fully explored.MethodsPDK and PD-L1 expression was analyzed using data from the GSE66229 and The Cancer Genome Atlas (TCGA) cohorts. Additionally, the Immune Checkpoint Blockade Therapy Atlas (ICBatlas) database was utilized to assess PDK expression in an immune checkpoint blockade (ICB) therapy group. Subsequently, the upregulation of PD-L1 and the enhancement of anticancer effects achieved by targeting PDK were validated through in vivo and in vitro assays. The impact of PDK on histone acetylation was investigated using ChIP‒qPCR to detect changes in histone acetylation levels.ResultsOur analysis revealed a notable negative correlation between PD-L1 and PDK expression. Downregulation of PDK led to a significant increase in PD-L1 expression. PDK inhibition increased histone acetylation levels by promoting acetyl-CoA generation. The augmentation of acetyl-CoA production and concurrent inhibition of histone deacetylation were found to upregulate PD-L1 expression in gastric cancer cells. Additionally, we observed a significant increase in the anticancer effect of PD-L1 antibodies following treatment with a PDK inhibitor.ConclusionsDownregulation of PDK in gastric cancer cells leads to an increase in PD-L1 expression levels, thus potentially improving the efficacy of PD-L1 immune checkpoint blockade therapy.

Melatonin mediates phenolic acids accumulation in barley sprouts under MeJA stress.

Phenolic acids are secondary metabolites in higher plants, with antioxidant, anticancer, and anti-aging effects on the human body. Therefore, foods rich in phenolic acids are popular. Methyl jasmonate (MeJA) promoted phenolic acids accumulation but also inhibited sprout growth. Melatonin (MT) was a new type of plant hormone that not only alleviated plants' abiotic stress, but also promoted the synthesis of plant-stimulating metabolism. This study aimed to elucidate the mechanism of exogenous MT on the growth and development, and phenolic acids metabolism of barley sprouts under MeJA treatment. The results showed that MT increased the phenolic acids content in sprouts by increasing the activities of phenylalanine ammonia-lyase and cinnamic acid 4-hydroxylase, and up-regulating the gene expression of phenylalanine ammonia-lyase, cinnamic acid 4-hydroxylase, 4-coumarate: coenzyme a ligase, and ferulic acid-5-hydroxylase. MT attenuated the growth inhibition of barley sprouts under MeJA stress by increasing the activities of regulated antioxidant enzymes and the expression of their corresponding genes. Furthermore, MT increased the NO content and induced Ca2+ burst in barley sprouts under MeJA stress. These events were inhibited by DL-4-Chlorophenylalanine. These results suggested that MT ameliorated growth inhibition and promoted the biosynthesis of phenolic acids in barley sprouts under MeJA stress.

Design, structural characterization, DFT, molecular docking, and chemotherapeutic activity of novel platinum(II) and palladium(II) complexes derived from Metformin-based Schiff base

Two novel bidentate Schiff bases ligands derived from Metformin with aldehydic molecules, including o-Ethoxy benzaldehyde (L1) and thiophene-2-carbaldehyde (L2) and Pt(II) and Pd(II) complexes were prepared. Numerous techniques were used to study the ligands and their metal complexes, including mass spectroscopy, IR, UV–Vis, molar conductivity, magnetic moment measurement, 1HNMR, PXRD, and 13CNMR. The preceding two Schiff bases were coordinated to Pd (II) and Pt (II) in the molar ratio of (1:1) (M:L) with the molecular structure [MLCl2]. The chemical quantum characteristics were calculated, and Schiff bases' optimized geometric structures and their complexes were revised theoretically. The MCF-7 breast cancer model was used to test the anticancer effects of metformin Schiff bases and their complexes in vitro. Additionally, using the EGFR tyrosine kinase of the selected proteins, a molecular docking study was carried out to learn more about the docking active site interactions. Ultimately, the conventional DPPH method was used to assess the antioxidant activity of the free ligands and their metal chelates. Pt (II) complexes demonstrated greater free radical scavenging activity than ascorbic acid. Furthermore, Pt (II) complexes showed more effective interactions with the selected mTOR protein, which is assumed to help the COVID-19 virus proliferate. Thus, Pt (II) has a bright future in the realm of chemotherapy.

A Computational Modeling Study on the Biomolecular Interactions of the Phytoconstituents of Nigella sativa with Anti-Apoptotic Proteins Mcl-1 and Bcl-x1

Cancer is the second leading cause of mortality worldwide. The strictly controlled physiological process of apoptosis is required for immune system function, maintenance of tissue homeostasis, and appropriate embryonic development. Anti-apoptotic proteins such as Bcl-xL and Mcl-1 are potent new anticancer targets. The inhibitory effect of the apparently therapeutic plant Nigella sativa on these targets is investigated using a molecular modeling approach in this work. From the molecular docking, we predict that seven compounds; apigenin, chlorogenic acid, hesperidin, quercetin, quercitrin, kaempferol, and rutin may have greater inhibitory potential against the target protein. These compounds have higher docking scores thus indicating higher binding affinities when compared to co-crystallized compounds. The co-compounds were crystallized with the standards, which served as the baselines for comparison studies. This result shows that that Nigella sativa compounds may be a potential anticancer drug that targets the anti-apoptotic protein. Targeting anti-apoptotic proteins provides clinical studies with the opportunity to evaluate for possible anti-cancer potential in the plant via other experimental models like rats and cancer cell lines. Using phytomedicines can equally augment existing therapy to provide synergistic anti-cancer effect when combined with existing drugs thereby enhancing therapy efficacy and because medicinal plants has lots of phytoconstituents, its use in this research can provide benefits of targeting multiple anti-apoptotic proteins thereby enhancing therapeutic effect unlike some conventional drugs that are mostly single targeting.

Harnessing Therapeutic Potentials of Biochanin A in Neurological Disorders: Pharmacokinetic and Pharmacodynamic Overview.

Biochanin A, an isoflavone flavonoid with estrogenic activity, is naturally found in red clover and other legumes. It possesses a wide range of pharmacological properties, including antioxidant, anti-inflammatory, anti-apoptotic, neuroprotective, and anticancer effects. In recent years, a growing body of pre-clinical research has focused on exploring the therapeutic potential of biochanin A in various neurological disorders, such as Alzheimer's and Parkinson's disease, multiple sclerosis, epilepsy, ischemic brain injury, gliomas, and neurotoxicity. This comprehensive review aims to shed light on the underlying molecular mechanisms that contribute to the neuroprotective role of biochanin A based on previous pre-clinical studies. Furthermore, it provides a detailed overview of the protective effects of biochanin A in diverse neurological disorders. The review also addresses the limitations associated with biochanin A administration and discusses different approaches employed to overcome these challenges. Finally, it highlights the future opportunities for translating biochanin A from pre-clinical research to clinical studies while also considering its commercial viability as a dietary supplement or a potential treatment for various diseases.

Unraveling the Mechanisms of Cannabidiol's Pharmacological Actions: A Comprehensive Research Overview.

Cannabis sativa has long been used for neurological and psychological healing. Recently, cannabidiol (CBD) extracted from cannabis sativa has gained prominence in the medical field due to its non-psychotropic therapeutic effects on the central and peripheral nervous systems. CBD, also acting as a potent antioxidant, displays diverse clinical properties such as anticancer, antiinflammatory, antidepressant, antioxidant, antiemetic, anxiolytic, antiepileptic, and antipsychotic effects. In this review, we summarized the structural activity relationship of CBD with different receptors by both experimental and computational techniques and investigated the mechanism of interaction between related receptors and CBD. The discovery of structural activity relationship between CBD and target receptors would provide a direction to optimize the scaffold of CBD and its derivatives, which would give potential medical applications on CBD-based therapies in various illnesses.

Phytosterols: Physiological Functions and Potential Application.

Dietary intake of natural substances to regulate physiological functions is currently regarded as a potential way of promoting health. As one of the recommended dietary ingredients, phytosterols that are natural bioactive compounds distributed in plants have received increasing attention for their health effects. Phytosterols have attracted great attention from scientists because of many physiological functions, for example, cholesterol-lowering, anticancer, anti-inflammatory, and immunomodulatory effects. In addition, the physiological functions of phytosterols, the purification, structure analysis, synthesis, and food application of phytosterols have been widely studied. Nowadays, many bioactivities of phytosterols have been assessed in vivo and in vitro. However, the mechanisms of their pharmacological activities are not yet fully understood, and in-depth investigation of the relationship between structure and function is crucial. Therefore, a contemporaneous overview of the extraction, beneficial properties, and the mechanisms, as well as the current states of phytosterol application, in the food field of phytosterols is provided in this review.

A Therapeutic Evaluation of Anticancer and Pharmacological Abilities on Tinospora cordifolia: A Systematic Review

Tinospora cordifolia (Tc), commonly called as Giloy, it is a herbaceous vine that is widely used in traditional medicine systems for its alleged anti-cancer effects. The purpose of this systematic study is to assess Tinospora cordifolia’s (Tc) medicinal potential against cancer. A thorough search of various scientific databases was done for studies looking at Tinospora cordifolia's anti-cancer properties. The findings demonstrate a varied variety of In vitro and In vivo research demonstrating Tinospora cordifolia’s (Tc) anti-proliferative, apoptotic and anti-metastatic activities against many cancer types, including breast, prostate, colon, and leukaemia. Mechanistic insights into its mode of action, such as modulation of signaling pathways involved in cell cycle regulation, apoptosis and angiogenesis, are presented. However, limitations in study designs, inconsistency in methodology, and differences in reported outcomes highlight the need for more well-designed clinical trials to evaluate Tinospora cordifolia's efficacy and safety as a potential supplementary medicine in cancer treatment regimens. Therapeutic plants, such as T. cordifolia, can strengthen the body's defences against disease and cure specific areas, displaying more body compatibility and fewer side effects than medications. In conjunction with this, the current study highlights T. cordifolia's pharmacological potential against a variety of illnesses.